Stock quote - Summary

Advanced Oncotherapy
AVO: 27.50 0.00 ( 0.00 %) delayed: 16:57PM
Bid price 26.00 High price 28.60
Ask price 29.00 Low price 26.15
Open price 28.10 Spread 10.34%
Prev close 27.50 Volume 54,203

Advanced Oncotherapy - Share price charts

Historic - 6 months

Advanced Advanced Oncotherapy charts >

Advanced Oncotherapy - Share price information
Name Advanced Oncotherapy Epic AVO
Activities Advanced Oncotherapy (formerly CareCapital Group plc) is a provider of new technology for innovative and patient-focused cancer treatments that helps clinicians to better serve patients and their families. These new alternatives are technological advances endorsed by specialists worldwide and locally here in the UK, but are not necessarily available in the NHS or the private sector. One important factor is that they all allow both patients and their families to return to their normal routines more quickly without compromising outcomes. As cancer treatment itself changes, the expectations of cancer patients have shifted around the world. The patient-doctor relationship is evolving towards shared decision making and increased patient engagement with their own health, holistically. Increasingly, patients want their values, lifestyles and preferences to be considered alongside clinical decisions. More than ever, clinicians and patients are working together to identify the most appropriate clinical options and to choose the optimal treatment plan. Shared decision making also recognises that there are complex trade-offs created by technology which can include time, perceived impact on quality of life and cost for clinicians, patients and payers. AVO is committed to increasing choices for effective treatment options to cancer patients, their families and their doctors, globally. ISIN GB00BD6SX109
Latest Share Price (p) 27.50 Net Gearing (%) 5.92
Market Capitalisation (pm) 22.26 Gross Gearing (%) 9.76
Shares in issue (m) 80.94 Debt Ratio 0.00
P/E Ratio -1.62 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.11
Dividend Yield (%) 0.00 Price to book value 0.65
Dividend Cover 0.00 ROCE (%) -38.81
Earning per share (p) -17.01 EPS Growth (%) -3,235.29
52-week high / low (p) 93.50 / 9.75 DPS Growth (%) n/a
Advanced Oncotherapy - Broker views
Date Broker Recommendation Price Old target price New target price Notes
27 Feb Beaufort Securities Hold - - Downgrades
25 Jan Beaufort Securities Speculative Buy - - Retains
24 Jan Beaufort Securities Speculative Buy - - Retains
23 Dec Beaufort Securities Speculative Buy - - Retains
16 Dec Beaufort Securities Speculative Buy - - Retains

More Advanced Oncotherapy broker views >

Advanced Oncotherapy - Director deals
Date Director Type Volume / Price Trade value
01 Aug 2017 Dr Enrico Vanni Buy 100,000 @ 17.75p £17,750.00
15 May 2017 Prof Steve Myers Buy 400,000 @ 26.00p £104,000.00
11 May 2017 Prof Christopher Nutting Buy 202,500 @ 24.67p £49,956.75
26 Apr 2017 Dr Mike Sinclair Buy 200,000 @ 30.44p £60,880.00
25 Apr 2017 Dr Enrico Vanni Buy 100,000 @ 26.96p £26,960.00

More Advanced Oncotherapy director deals >

Risk warning: Remember the price of shares can go down as well as up, and you are not guaranteed to get back the amount that you originally invested.
Click here to read the full warning.